Cover Image
市場調查報告書

生物醫藥品的全球市場:分析與預測

Global Biopharmaceutical Market Report & Forecast (2017-2021)

出版商 IMARC Services Pvt. Ltd. 商品編碼 367470
出版日期 內容資訊 英文 207 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物醫藥品的全球市場:分析與預測 Global Biopharmaceutical Market Report & Forecast (2017-2021)
出版日期: 2017年04月03日 內容資訊: 英文 207 Pages
簡介

本報告提供全球生物醫藥品的市場相關分析,整體市場規模的成果值、預測值,及各地區及各症狀、各類藥物的詳細趨勢,主要企業簡介與業績,代表性產品的概要銷售業績、預測,產業整體競爭力 (SWOT分析) 的資訊彙整,為您概述為以下內容。

第1章 序章

第2章 市場定義和分析方法

第3章 摘要整理

第4章 簡介

第5章 全球生物醫藥品市場

  • 市場的成果與預測
  • 各地區市場
  • 各適應症的市場
    • 自體免疫疾病
    • 腫瘤
    • 代謝障礙
    • 其他
  • 各類藥物的市場
    • 基因改造蛋白質
    • 單株抗體
    • 純化蛋白質
  • 競爭環境
    • 大生物醫藥品企業
    • 代表性生物醫藥品
  • 價值鏈分析
  • 波特的五力分析

第6章 北美

  • 美國
  • 加拿大

第7章 南美

  • 墨西哥
  • 巴西
  • 阿根廷

第8章 歐洲

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 俄羅斯
  • 土耳其

第9章 亞太地區

  • 日本
  • 中國
  • 澳洲
  • 韓國
  • 印度

第10章 SWOT分析

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SRP00116IW

The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry's multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.

The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales. Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.

The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada. Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.

IMARC's new report "Global Biopharmaceutical Market Report & Forecast (2017-2021)" gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2021. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.

What We Have Achieved in this Report?

Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market

Key Aspects Analyzed:

  • Driving Factors
  • Restraining Factors
  • Market Opportunities
  • Threats
  • Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics

Regions/Countries Covered:

  • North America: United States and Canada
  • Latin America: Mexico, Brazil and Argentina
  • Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
  • Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia
  • Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins

Focus of the Analysis for Each Country:

  • Total Market Performance
  • Performance of Various Classes
  • Performance of Top Players
  • Market Forecast

Key Questions Answered in this Report:

  • What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
  • What are the key opportunities and threats faced by the biopharmaceutical industry?
  • What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
  • Which are the world's largest biopharmaceutical markets?
  • Which are the world's fastest growing biopharmaceutical markets?
  • What is the structure and composition of various biopharmaceutical markets across the globe?
  • Which are the world's largest biopharmaceutical segments?
  • Which are the world's fastest growing biopharmaceutical segments?
  • Who are the world's largest biopharmaceutical companies and how have they performed in recent years?

Table of Contents

1 Preface

2 Research Methodology and Market Definitions

3 Executive Summary

4 Introduction

5 Global Biopharmaceutical Market

  • 5.1 Market Performance and Forecast
    • 5.1.1 Current Performance (2009-2016)
    • 5.1.2 Market Forecast (2017-2021)
  • 5.2 Market by Region
    • 5.2.1 Current Performance (2009-2016)
    • 5.2.2 Market Forecast (2017-2021)
  • 5.3 Market by Indication
    • 5.3.1 Autoimmune Diseases
    • 5.3.2 Oncology
    • 5.3.3 Metabolic Disorders
    • 5.3.4 Others
  • 5.4 Market by Class
    • 5.4.1 Recombinant Proteins
      • 5.4.1.1 Current Performance (2009-2016)
      • 5.4.1.2 Market Forecast (2017-2021)
    • 5.4.2 Monoclonal Antibodies
      • 5.4.2.1 Current Performance (2009-2016)
      • 5.4.2.2 Market Forecast (2017-2021)
    • 5.4.3 Purified Proteins
      • 5.4.3.1 Current Performance (2009-2016)
      • 5.4.3.2 Market Forecast (2017-2021)
  • 5.5 Competitive Landscape
    • 5.5.1 Top Biopharmaceutical Players
      • 5.5.1.1 Roche
      • 5.5.1.1.1 Company Overview
      • 5.5.1.1.2 Key Financials
      • 5.5.1.2 Amgen
      • 5.5.1.2.1 Company Overview
      • 5.5.1.2.2 Key Financials
      • 5.5.1.3 Novo Nordisk
      • 5.5.1.3.1 Company Overview
      • 5.5.1.3.2 Key Financials
      • 5.5.1.4 AbbVie
      • 5.5.1.4.1 Company Overview
      • 5.5.1.4.2 Key Financials
      • 5.5.1.5 Sanofi S.A
      • 5.5.1.5.1 Company Overview
      • 5.5.1.5.2 Key Financials
    • 5.5.2 Top Biopharmaceutical Drugs
      • 5.5.2.1 Humira
      • 5.5.2.2 Enbrel
      • 5.5.2.3 Rituxan
      • 5.5.2.4 Avastin
      • 5.5.2.5 Lantus
  • 5.6 Value Chain Analysis
  • 5.7 Porter's Five Forces Analysis
    • 5.7.1 Overview
    • 5.7.2 Bargaining Power of Buyers
    • 5.7.3 Bargaining Power of Suppliers
    • 5.7.4 Degree of Rivalry
    • 5.7.5 Threat of New Entrants
    • 5.7.6 Threat of Substitutes

6 North America

  • 6.1 United States
    • 6.1.1 Market Performance (2009-2016)
    • 6.1.2 Market by Class
      • 6.1.2.1 Recombinant Proteins
      • 6.1.2.2 Monoclonal Antibodies
      • 6.1.2.3 Purified Proteins
    • 6.1.3 Performance of Top Players
    • 6.1.4 Market Forecast (2017-2021)
  • 6.2 Canada
    • 6.2.1 Market Performance (2009-2016)
    • 6.2.2 Market by Class
      • 6.2.2.1 Recombinant Proteins
      • 6.2.2.2 Monoclonal Antibodies
      • 6.2.2.3 Purified Proteins
    • 6.2.3 Performance of Top Players
    • 6.2.4 Market Forecast (2017-2021)

7 Latin America

  • 7.1 Mexico
    • 7.1.1 Market Performance (2009-2016)
    • 7.1.2 Market by Class
      • 7.1.2.1 Recombinant Proteins
      • 7.1.2.2 Monoclonal Antibodies
      • 7.1.2.3 Purified Proteins
    • 7.1.3 Performance of Top Players
    • 7.1.4 Market Forecast (2017-2021)
  • 7.2 Brazil
    • 7.2.1 Market Performance (2009-2016)
    • 7.2.2 Market by Class
      • 7.2.2.1 Recombinant Proteins
      • 7.2.2.2 Monoclonal Antibodies
      • 7.2.2.3 Purified Proteins
    • 7.2.3 Performance of Top Players
    • 7.2.4 Market Forecast (2017-2021)
  • 7.3 Argentina
    • 7.3.1 Market Performance (2009-2016)
    • 7.3.2 Market by Class
      • 7.3.2.1 Recombinant Proteins
      • 7.3.2.2 Monoclonal Antibodies
      • 7.3.2.3 Purified Proteins
    • 7.3.3 Performance of Top Players
    • 7.3.4 Market Forecast (2017-2021)

8 Europe

  • 8.1 Germany
    • 8.1.1 Market Performance (2009-2016)
    • 8.1.2 Market by Class
      • 8.1.2.1 Recombinant Proteins
      • 8.1.2.2 Monoclonal Antibodies
      • 8.1.2.3 Purified Proteins
    • 8.1.3 Performance of Top Players
    • 8.1.4 Market Forecast (2017-2021)
  • 8.2 France
    • 8.2.1 Market Performance (2009-2016)
    • 8.2.2 Market by Class
      • 8.2.2.1 Recombinant Proteins
      • 8.2.2.2 Monoclonal Antibodies
      • 8.2.2.3 Purified Proteins
    • 8.2.3 Performance of Top Players
    • 8.2.4 Market Forecast (2017-2021)
  • 8.3 Italy
    • 8.3.1 Market Performance (2009-2016)
    • 8.3.2 Market by Class
      • 8.3.2.1 Recombinant Proteins
      • 8.3.2.2 Monoclonal Antibodies
      • 8.3.2.3 Purified Proteins
    • 8.3.3 Performance of Top Players
    • 8.3.4 Market Forecast (2017-2021)
  • 8.4 Spain
    • 8.4.1 Market Performance (2009-2016)
    • 8.4.2 Market by Class
      • 8.4.2.1 Recombinant Proteins
      • 8.4.2.2 Monoclonal Antibodies
      • 8.4.2.3 Purified Proteins
    • 8.4.3 Performance of Top Players
    • 8.4.4 Market Forecast (2017-2021)
  • 8.5 United Kingdom
    • 8.5.1 Market Performance (2009-2016)
    • 8.5.2 Market by Class
      • 8.5.2.1 Recombinant Proteins
      • 8.5.2.2 Monoclonal Antibodies
      • 8.5.2.3 Purified Proteins
    • 8.5.3 Performance of Top Players
    • 8.5.4 Market Forecast (2017-2021)
  • 8.6 Russia
    • 8.6.1 Market Performance (2009-2016)
    • 8.6.2 Market by Class
      • 8.6.2.1 Recombinant Proteins
      • 8.6.2.2 Monoclonal Antibodies
      • 8.6.2.3 Purified Proteins
    • 8.6.3 Performance of Top Players
    • 8.6.4 Market Forecast (2017-2021)
  • 8.7 Turkey
    • 8.7.1 Market Performance (2009-2016)
    • 8.7.2 Market by Class
      • 8.7.2.1 Recombinant Proteins
      • 8.7.2.2 Monoclonal Antibodies
      • 8.7.2.3 Purified Proteins
    • 8.7.3 Performance of Top Players
    • 8.7.4 Market Forecast (2017-2021)

9 Asia Pacific

  • 9.1 Japan
    • 9.1.1 Market Performance (2009-2016)
    • 9.1.2 Market by Class
      • 9.1.2.1 Recombinant Proteins
      • 9.1.2.2 Monoclonal Antibodies
      • 9.1.2.3 Purified Proteins
    • 9.1.3 Performance of Top Players
    • 9.1.4 Market Forecast (2017-2021)
  • 9.2 China
    • 9.2.1 Market Performance (2009-2016)
    • 9.2.2 Market by Class
      • 9.2.2.1 Recombinant Proteins
      • 9.2.2.2 Monoclonal Antibodies
      • 9.2.2.3 Purified Proteins
    • 9.2.3 Performance of Top Players
    • 9.2.4 Market Forecast (2017-2021)
  • 9.3 Australia
    • 9.3.1 Market Performance (2009-2016)
    • 9.3.2 Market by Class
      • 9.3.2.1 Recombinant Proteins
      • 9.3.2.2 Monoclonal Antibodies
      • 9.3.2.3 Purified Proteins
    • 9.3.3 Performance of Top Players
    • 9.3.4 Market Forecast (2017-2021)
  • 9.4 South Korea
    • 9.4.1 Market Performance (2009-2016)
    • 9.4.2 Market by Class
      • 9.4.2.1 Recombinant Proteins
      • 9.4.2.2 Monoclonal Antibodies
      • 9.4.2.3 Purified Proteins
    • 9.4.3 Performance of Top Players
    • 9.4.4 Market Forecast (2017-2021)
  • 9.5 India
    • 9.5.1 Market Performance (2009-2016)
    • 9.5.2 Market by Class
      • 9.5.2.1 Recombinant Proteins
      • 9.5.2.2 Monoclonal Antibodies
      • 9.5.2.3 Purified Proteins
    • 9.5.3 Performance of Top Players
    • 9.5.4 Market Forecast (2017-2021)
  • 9.6 Indonesia
    • 9.6.1 Market Performance (2009-2016)
    • 9.6.2 Market by Class
      • 9.6.2.1 Recombinant Proteins
      • 9.6.2.2 Monoclonal Antibodies
      • 9.6.2.3 Purified Proteins
    • 9.6.3 Performance of Top Players
    • 9.6.4 Market Forecast (2017-2021)

10 SWOT Analysis

  • 10.1 Strengths
    • 10.1.1 High Efficacy and Target Oriented Attack
    • 10.1.2 Strong Potential to Achieve Blockbuster
    • 10.1.3 Limited Generic Threat
    • 10.1.4 High Approval Success Rates
  • 10.2 Weaknesses
    • 10.2.1 Inconvenient Drug Delivery
    • 10.2.2 Short Half Lives
    • 10.2.3 Second Line of Therapy
    • 10.2.4 High Cost of Therapy
    • 10.2.5 Incidence of Unfavorable Side Effects
  • 10.3 Opportunities
    • 10.3.1 Diseases with High Unmet Needs
    • 10.3.2 Approval into Additional Indications
    • 10.3.3 Emerging Markets
    • 10.3.4 New Approvals and a Strong Pipeline
  • 10.4 Threats
    • 10.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
    • 10.4.2 Biosimilars
    • 10.4.3 Limited and Conditional Reimbursement
    • 10.4.4 Uncertainties in the Economic Environment

List of Figures

Figure 3-1: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 4-1: Complexity of Biopharmaceuticals

Figure 4-2: Sources of Biopharmaceuticals

Figure 5-1: Global: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 5-2: Global: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 5-3: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2016

Figure 5-4: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2021

Figure 5-5: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2016

Figure 5-6: Global: Autoimmune Biopharmaceutical Market (in Million US$), 2016 & 2021

Figure 5-7: Global: Oncology Biopharmaceutical Market (in Million US$), 2016 & 2021

Figure 5-8: Global: Metabolic Disorders Biopharmaceutical Market (in Million US$), 2016 & 2021

Figure 5-9: Global: Others Biopharmaceutical Market (in Million US$), 2016 & 2021

Figure 5-10: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 5-11: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2017-2021

Figure 5-12: Global: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 5-13: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 5-14: Global: Recombinant Proteins Market Forecast (in Million US$), 2017-2021

Figure 5-15: Global: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 5-16: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 5-17: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2017-2021

Figure 5-18: Global: Purified Proteins Market (in Million US$), 2009-2016

Figure 5-19: Global: Purified Proteins Market: Sales Share by Class (in %), 2016

Figure 5-20: Global: Purified Proteins Market Forecast (in Million US$), 2017-2021

Figure 5-21: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 5-22: Roche: Sales Value Trend (in Billion US$), 2011-2015

Figure 5-23: Roche: Revenue Breakup by Region (in %), 2015

Figure 5-24: Amgen: Sales Value Trend (in Billion US$), 2011-2015

Figure 5-25: Amgen: Revenue Breakup by Region (in %), 2015

Figure 5-26: Novo Nordisk: Sales Value Trend (in Billion US$), 2011-2015

Figure 5-27: Novo Nordisk: Revenue Breakup by Region (in %), 2015

Figure 5-28: AbbVie: Sales Value Trend (in Billion US$), 2011-2015

Figure 5-29: AbbVie: Revenue Breakup by Region (in %), 2015

Figure 5-30: Sanofi S.A: Sales Value Trend (in Billion US$), 2011-2015

Figure 5-31: Sanofi S.A: Revenue Breakup by Region (in %), 2015

Figure 5-32: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %), 2016

Figure 5-33: Global: Humira Market: Sales Value (in Billion US$), 2010-2015

Figure 5-34: Global: Enbrel Market: Sales Value (in Billion US$), 2010-2015

Figure 5-35: Global: Rituxan Market: Sales Value (in Billion US$), 2010-2015

Figure 5-36: Global: Avastin Market: Sales Value (in Billion US$), 2010-2015

Figure 5-37: Global: Lantus Market: Sales Value (in Billion US$), 2010-2015

Figure 5-38: Global: Biopharmaceutical Industry: Value Chain Analysis

Figure 5-39: Biopharmaceutical Industry: Porter's Five Forces Analysis

Figure 6-1: United States: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 6-2: United States: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 6-3: United States: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 6-4: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 6-5: United States: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 6-6: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 6-7: United States: Purified Proteins Market (in Million US$), 2009-2016

Figure 6-8: United States: Purified Proteins Market: Sales Share by Class (in %), 2016

Figure 6-9: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 6-10: United States: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 6-11: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 6-12: Canada: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 6-13: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 6-14: Canada: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 6-15: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 6-16: Canada: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 6-17: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 6-18: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 6-19: Canada: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 6-20: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 7-1: Mexico: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 7-2: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 7-3: Mexico: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 7-4: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 7-5: Mexico: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 7-6: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 7-7: Mexico: Purified Proteins Market (in '000 US$), 2009-2016

Figure 7-8: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 7-9: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 7-10: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 7-11: Brazil: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 7-12: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 7-13: Brazil: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 7-14: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 7-15: Brazil: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 7-16: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 7-17: Brazil: Purified Proteins Market (in Million US$), 2009-2016

Figure 7-18: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 7-19: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 7-20: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 7-21: Argentina: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 7-22: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 7-23: Argentina: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 7-24: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 7-25: Argentina: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 7-26: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 7-27: Argentina: Purified Proteins Market (in Million US$), 2009-2016

Figure 7-28: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 7-29: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 7-30: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 8-1: Germany: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 8-2: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 8-3: Germany: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 8-4: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 8-5: Germany: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 8-6: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 8-7: Germany: Purified Proteins Market (in Million US$), 2009-2016

Figure 8-8: Germany: Purified Proteins Market: Sales Share by Class (in %), 2016

Figure 8-9: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 8-10: Germany: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 8-11: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 8-12: France: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 8-13: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 8-14: France: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 8-15: France: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 8-16: France: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 8-17: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 8-18: France: Purified Proteins Market (in Million US$), 2009-2016

Figure 8-19: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 8-20: France: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 8-21: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 8-22: Italy: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 8-23: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 8-24: Italy: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 8-25: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 8-26: Italy: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 8-27: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 8-28: Italy: Purified Proteins Market (in Million US$), 2009-2016

Figure 8-29: Italy: Biopharmaceutical Market: Sales Share of Top players (in %), 2016

Figure 8-30: Italy: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 8-31: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 8-32: Spain: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 8-33: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 8-34: Spain: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 8-35: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 8-36: Spain: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 8-37: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 8-38: Spain: Purified Proteins Market (in Million US$), 2009-2016

Figure 8-39: Spain: Purified Proteins Market: Sales Share by Class (in %), 2016

Figure 8-40: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 8-41: Spain: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 8-42: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 8-43: UK: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 8-44: UK: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 8-45: UK: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 8-46: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 8-47: UK: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 8-48: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 8-49: UK: Purified Proteins Market (in Million US$), 2009-2016

Figure 8-50: UK: Purified Proteins Market: Sales Share by Class (in %), 2016

Figure 8-51: UK: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 8-52: UK: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 8-53: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 8-54: Russia: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 8-55: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 8-56: Russia: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 8-57: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 8-58: Russia: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 8-59: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 8-60: Russia: Purified Proteins Market (in Million US$), 2009-2016

Figure 8-61: Russia: Purified Proteins Market: Sales Share by Class (in %), 2016

Figure 8-62: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 8-63: Russia: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 8-64: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 8-65: Turkey: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 8-66: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 8-67: Turkey: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 8-68: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 8-69: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 8-70: Turkey: Purified Proteins Market (in Million US$), 2009-2016

Figure 8-71: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 8-72: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 8-73: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 9-1: Japan: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 9-2: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 9-3: Japan: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 9-4: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 9-5: Japan: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 9-6: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 9-7: Japan: Purified Proteins Market (in Million US$), 2009-2016

Figure 9-8: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 9-9: Japan: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 9-10: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 9-11: China: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 9-12: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 9-13: China: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 9-14: China: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 9-15: China: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 9-16: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 9-17: China: Purified Proteins Market (in Million US$), 2009-2016

Figure 9-18: China: Purified Proteins Market: Sales Share by Class (in %), 2016

Figure 9-19: China: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 9-20: China: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 9-21: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 9-22: Australia: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 9-23: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 9-24: Australia: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 9-25: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 9-26: Australia: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 9-27: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 9-28: Australia: Purified Proteins Market (in Million US$), 2009-2016

Figure 9-29: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 9-30: Australia: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 9-31: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 9-32: South Korea: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 9-33: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 9-34: South Korea: Recombinant Proteins Market (in Million US$), 2008-2016

Figure 9-35: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 9-36: South Korea: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 9-37: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2016

Figure 9-38: South Korea: Purified Proteins Market (in Million US$), 2009-2016

Figure 9-39: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2016

Figure 9-40: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 9-41: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 9-42: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 9-43: India: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 9-44: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 9-45: India: Recombinant Proteins Market (in Million US$), 2009-2016

Figure 9-46: India: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 9-47: India: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 9-48: India: Purified Proteins Market (in Million US$), 2009-2016

Figure 9-49: India: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 9-50: India: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 9-51: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 9-52: Indonesia: Biopharmaceutical Market (in Million US$), 2009-2016

Figure 9-53: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016

Figure 9-54: Indonesia: Recombinant Proteins Market (in Million US$), 2008-2016

Figure 9-55: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2016

Figure 9-56: Indonesia: Monoclonal Antibodies Market (in Million US$), 2009-2016

Figure 9-57: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016

Figure 9-58: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016

Figure 9-59: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2017-2021

Figure 9-60: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021

Figure 10-1: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2000& 2015

Figure 10-2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products

Figure 10-3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used

Figure 10-4: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)

Figure 10-5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)

Figure 10-6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals and Small Molecule Drugs (in US$)

Figure 10-7: Emerging Biopharmaceutical Market Forecast (in Million US$), 2016 & 2021

Figure 10-8: Developed Biopharmaceutical Market Forecast (in Million US$), 2016 & 2021

Figure 10-9: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2001-2016

Figure 10-10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in %), 2001-2016

Figure 10-11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total Pharmaceutical Market & Phase III development (%)

Figure 10-12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)

Figure 10-13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market (in Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09

Figure 10-14: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)

Figure 10-15: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2011

Figure 10-16: Germany, France, Italy, Spain & UK: Epoetin AlfaBiosimilars: Patient Share (in %), 2007-2011

Figure 10-17: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2011

Figure 10-18: Current Medicare Payer Coverage for Monoclonal Antibodies

Figure 10-19: Performance of Biotech Stocks During the Financial Crisis (in %), Jan 2008 to Dec 2008

List of Tables

Table 2-1: Global: Biopharmaceutical Market: Definition & Segmentation

Table 3-1: Global: Biopharmaceutical Market: SWOT Analysis

Table 3-2: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2017 & 2021

Table 4-1: Differences Between Small Molecule Drugs & Biopharmaceuticals

Table 4-2: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs

Table 5-1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2009-2016

Table 5-2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2017-2021

Table 5-3: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2016

Table 5-4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth (in Million US$), 2017-2021

Table 5-5: Roche: Financial Data (in US$ Million), 2011-2015

Table 5-6: Amgen: Financial Data (in US$ Million), 2011-2015

Table 5-7: Novo Nordisk: Financial Data (in US$ Million), 2011-2015

Table 5-8: AbbVie: Financial Data (in US$ Million), 2011-2015

Table 5-9: Sanofi S.A.: Financial Data (in US$ Million), 2011-2015

Table 5-10: Global: Biopharmaceutical Market: Sales of Top Biopharmaceuticals (in Million US$), 2015

Table 10-1: Global: Top Ten Selling Drugs (Based on Origin), 2000

Table 10-2: Global: Top Ten Selling Drugs (Based on Origin), 2015

Table 10-3: Mode of Administration of Popular Biotech Drugs

Table 10-4: FDA: Total Number of Biopharmaceutical Approvals in 2015

Back to Top